Bladder Cancer Diagnosis by FISH (UroVysion)
UroVysion is a molecular cytology test that detects aneuploidy of chromosomes 3, 7, and 17 and deletion of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from subjects with transitional cell carcinoma of the bladder. Bladder cancer is the fourth most common cancer in men and the eighth most common cancer in women over the age of 40. Risk factors include smoking, carcinogens, and certain parasitic infections. Most bladder cancers are non-invasive superficial cancer. The most common histologic type of bladder cancer, acounting for ninety percent of cases, is transitional cell carcinomas (TCC), while the remaining 10% are predominantly squamous cell or adenocarcinomas. Most bladder cancer is found during the early treatable stage. However, even when found during the early stage, bladder cancer is likely to recur. Diagnostic modalities include physical exam, urinalysis (looking at the chemical constituents of urine including blood and white blood cells), cytology (looking specifically for unusual or malignant cells), cystoscopy, and tissue biopsy. Tissue samples will be evaluated by a pathologist in order to confer a histologic type (give it a name) and to grade the cancer (an evaluation of aggressiveness of the tumor). Staging is also done to aid a physician in selecting treatment. The stage of a cancer, including bladder, is an assessment of three components: The tumor itself, the lymph node status, and the presence of distant metastases. These three components are combined into a single stage, which uses numbers and letters. These are the stages of bladder cancer:
Stage 0: The cancer cells are found only on the surface of the inner lining of the bladder. The doctor may call this carcinoma in situ.
Stage I: The tumor has grown through the surface into the superficial lamina propria of the bladder. But it has not invaded the true muscle layer (muscularis propria) of the bladder.
Stage II: The tumor has invaded the true muscle layer of the bladder, but has not extended through it.
Stage III: The tumor has grown through the muscle layer to reach tissues surrounding the bladder, such as the fat surrounding the bladder (whether macroscopically or microscopically). This stage also includes invasion of other organs such as the prostate, uterus, or vagina. Lymph nodes are not involved in this stage, it does not involve the pelvic or abdominal walls, and there are no distant metastases.
Stage IV: One of the following: 1) The tumor has invaded through the bladder into the wall of the pelvis or abdomen, but cancer is not found in any lymph nodes. Or 2) The cancer has spread to at least one lymph node but not to distant organs OR the cancer has spread to to parts of the body far away from the bladder, such as the liver, lungs, or bones.
Each subgroup differs in clinical outcome. At presentation, 75% of tumors are "superficial" (i.e., pTa, pT1 or pTIS), of which 50 to 80% will have one or several recurrences, and 15 to 25% will progress to invasive tumors. For this reason, patients with "superficial" bladder cancer are regularly monitored for tumor recurrence and progression with cystoscopy and sometimes urine cytology. Cystoscopic examination of the bladder, and often urine cytology, are also standard care for patients >40 years of age and presenting with hematuria.
- As an aid in initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer
- Monitor noninvasive urothelial carcinoma in conjunction with cystoscopy in patients with previously diagnosed bladder cancer to identify residual or recurring urothelial carcinoma
- Differential diagnose of bladder cancer in patients with hematuria (in conjunction with standard diagnostic procedures)
- A positive result is consistent with a diagnosis of bladder cancer or bladder cancer recurrence, either in the bladder or in another site within the urinary system.
- Positive results are called when specimens from patients with bladder cancer show ≥4 cells with multiple chromosomal gains or ≥ 12 cells with the loss of both copies of 9p21.
- Negative results indicate a lack of evidence for the presence of numeric chromosomal abnormalities commonly associated with urothelial carcinoma. A negative result is suggestive of the absence of bladder cancer, but does not rule it out.
- The UroVysionTM Bladder Cancer assay will detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer.
- The test requires that a certain number of viable cells be assessed. It is important to note that a positive test may be caused by cancers other than primary urothelial carcinoma of the bladder, such as urothelial carcinoma arising in the renal pelvis, primary cancers of the kidney such as renal cell carcinoma, primary cancers of the prostate such as prostatic acinar adenocarcinoma or a cancer that has metastasized to the genitourinary tract.
Negative
35 mL of voided urine specimens collected in PresevCyt.
Stability
- Refrigerated: 72 hours (fixed in PreservCyt fixative)
- Cancer Genet Cytogenet. 1997;95:108-115. [PMID: 9140460]
- Med Sci Monit. 2001 Jan-Feb;7(1):164-8. [PMID: 11208514]
- N Engl J Med. 1990;322(16):1129-1138. [PMID: 2181313]
- Semin Oncol. 2007 Apr;34(2):73-4. [PMID: 17382790]
- Scand J Urol Nephrol Suppl. 2008 Sep;(218):166-74. [PMID: 18815931]
- Fair WR, Fuks ZY, Scher HI. Cancer: Principles & Practice of Oncology, 4th ed. (ed. DeVita VT, Hellman S, Rosenberg SA). J.B. Lippincott Co., Philadelphia, PA. 1993:1052-1072.
- UroVysion^TM Bladder Cancer Kit - P030052. Food and Drug Administration Website. Available at: http://www.fda.gov/cdrh/pdf3/p030052b.pdf. Accessed 7/8/11.